The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Open accessAbstract
BACKGROUND: Patients with hemophilia A rely on exogenous factor VIII to prevent bleeding in joints, soft tissue, and the central nervous system. Although successful gene transfer has been reported in patients with hemophilia B, the large size of the factor VIII coding region has precluded improved outcomes with gene therapy in patients with hemophilia A. METHODS: We infused a single intravenous dose of a codon-optimized adeno-associated virus serotype 5 (AAV5) vector encoding a B-domain-deleted human factor VIII (AAV5-hFVIII-SQ) in nine men with severe hemophilia A. Participants were enrolled sequentially into one of three dose cohorts (low dose [one participant], intermediate dose [one participant], and high dose [seven participants]) and were followed through 52 weeks. RESULTS: Factor VIII activity levels remained at 3 IU or less per deciliter in the recipients of the low or intermediate dose. In the high-dose cohort, the factor VIII activity level was more than 5 IU per deciliter between weeks 2 and 9 after gene transfer in all seven participants, and the level in six participants increased to a normal value (>50 IU per deciliter) that was maintained at 1 year after receipt of the dose. In the high-dose cohort, the median annualized bleeding rate among participants who had previously received prophylactic therapy decreased from 16 events before the study to 1 event after gene transfer, and factor VIII use for participant-reported bleeding ceased in all the participants in this cohort by week 22. The primary adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper limit of the normal range or less. Progression of preexisting chronic arthropathy in one participant was the only serious adverse event. No neutralizing antibodies to factor VIII were detected. CONCLUSIONS: The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stabilization of hemostasis and a profound reduction in factor VIII use in all seven participants. In this small study, no safety events were noted, but no safety conclusions can be drawn. (Funded by BioMarin Pharmaceutical; ClinicalTrials.gov number, NCT02576795 ; EudraCT number, 2014-003880-38 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both transgene products, FVIII-SQ and FIX-R338L, demonstrate variable activity measurements in OSA versus chromogenic assay (CSA) determinants of factor activity that are reproducible across trials.144,145,149,152”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“multiple HA and HB trials have demonstrated ≥10-fold variability in FVIII:C/FIX:C with the same vector and dose (Harrington et al., 2020, WFH Virtual Summit, conference).145,149,150,153”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [149]
In the citing paper
“Corticosteroids are the most commonly used agents to resolve transaminitis, however, its relationship with resolution by corticosteroids and T-cell response are not always clear as observed in a hemophilia A trial (28, 105).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [28]
In the citing paper
“clinical gene therapy using a codon-optimized exogenous construct to compensate for mutations in a nuclear gene (e.g. hemophilia, [69]) is ongoing”
From Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950
Guidelines for the management of hemophilia
Srivastava, A., Brewer, A., Mauser‐Bunschoten, E. P., Key, N. S., Kitchen, S., Llinás, A. M., Ludlam, C. A., Mahlangu, J. N., Mulder, K., Poon, M., et al. (2012) · Haemophilia · doi:10.1111/j.1365-2516.2012.02909.x · Cited by 1,949
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Antioxidants reduce endoplasmic reticulum stress and improve protein secretion
Malhotra, J. D., Miao, H. Z., Zhang, K., Wolfson, A., Pennathur, S., Pipe, S. W., & Kaufman, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809677105 · Cited by 682
Flagged first, then by citations
Research works printed but not linked: 1
- Falese L, Gene Ther
Cited by
Sorted by citations
Items 201–300 of 692
An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs
Sun, J., Shao, W., Chen, X., Merricks, E. P., Wimsey, L., Abajas, Y. L., Niemeyer, G. P., Lothrop, C. D., Monahan, P. E., Samulski, R. J., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.07.011 · Cited by 30
O’Mahony, B., Dunn, A. L., Leavitt, A. D., Peyvandi, F., Ozelo, M. C., Mahlangu, J. N., Peerlinck, K., Wang, J., Lowe, G., Tan, C.-W., et al. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.08.032 · Cited by 30
Self-citationМакаревич, П. И., Efimenko, A. Y., & Va, T. (2020) · Biochemistry (Moscow) · doi:10.1134/s0006297920010022 · Cited by 30
In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
Breuer, C. B., Hanlon, K. S., Natasan, J.-S., Volak, A., Meliani, A., Mingozzi, F., Kleinstiver, B. P., Moon, J. J., & Maguire, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61518-w · Cited by 30
Baculoviruses in Gene Therapy and Personalized Medicine
Schaly, S., Ghebretatios, M., & Prakash, S. (2021) · Biologics · doi:10.2147/btt.s292692 · Cited by 30
Chen, N., Sun, K., Chemuturi, N. V., Cho, H., & Xia, C. Q. (2022) · The AAPS Journal · doi:10.1208/s12248-021-00678-7 · Cited by 30
Clinical Pharmacology Considerations on Recombinant Adeno‐Associated Virus–Based Gene Therapy
Sun, K., & Liao, M. Z. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2141 · Cited by 30
Waddington, S. N., Peranteau, W. H., Rahim, A. A., Boyle, A. K., Kurian, M. A., Gissen, P., Chan, J. K. Y., & David, A. L. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12659 · Cited by 31
Gene Therapy for Pompe Disease: The Time is now
Colella, P., & Mingozzi, F. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.109 · Cited by 31
The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges
Trinchero, A., Sholzberg, M., & Matino, D. (2020) · Hämostaseologie · doi:10.1055/a-1175-6530 · Cited by 30
The immune response to the fVIII gene therapy in preclinical models
Patel, S. R., Lundgren, T. S., Spencer, H. T., & Doering, C. B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00494 · Cited by 29
Yin, L., Keeler, G. D., Zhang, Y., Hoffman, B. E., Ling, C., Qing, K., & Srivastava, A. (2020) · Gene Therapy · doi:10.1038/s41434-020-0140-1 · Cited by 29
Belov, A. A., Schultz, K. L. W., Forshee, R. A., & Tegenge, M. A. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12597 · Cited by 29
Gene Therapy and Hemophilia: Where Do We Go from Here?
Bolous, N. S., Bhatt, N., Bhakta, N. H., Neufeld, E. J., Davidoff, A. M., & Reiss, U. M. (2022) · Journal of Blood Medicine · doi:10.2147/jbm.s371438 · Cited by 29
Hemophilia gene therapy: first, do no harm
Valentino, L. A., Kaczmarek, R., Pierce, G. F., Noone, D., O’Mahony, B., Page, D., Rotellini, D., & Skinner, M. W. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.06.016 · Cited by 29
Self-citationGonzalez‐Fernandez, T., Kelly, D. J., & O’Brien, F. J. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800038 · Cited by 30
In vivo applications and toxicities of AAV-based gene therapies in rare diseases
Zhao, Q., Peng, H., Ma, Y., Yuan, H., & Jiang, H. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03893-z · Cited by 30
Ginocchio, V. M., Ferla, R., Auricchio, A., & Brunetti‐Pierri, N. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.151 · Cited by 29
A primer to gene therapy: Progress, prospects, and problems
Zittersteijn, H. A., Gonçalves, M. A. F. V., & Hoeben, R. C. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12270 · Cited by 28
Genome editing using CRISPR/Cas9 to treat hereditary hematological disorders
Chen, Y., Wen, R., Yang, Z., & Chen, Z. (2021) · Gene Therapy · doi:10.1038/s41434-021-00247-9 · Cited by 29
Hart, D. P., Branchford, B. R., Hendry, S., Ledniczky, R., Sidonio, R. F., Négrier, C., Kim, M. H., Rice, M., Minshall, M., Arcé, C., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01555-w · Cited by 28
Liver-Directed Adeno-Associated Virus–Mediated Gene Therapy for Mucopolysaccharidosis Type VI
Brunetti‐Pierri, N., Ferla, R., Ginocchio, V. M., Rossi, A., Fecarotta, S., Romanò, R., Parenti, G., Yıldız, Y., Zancan, S., Pecorella, V., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200052 · Cited by 28
Nathwani, A. C., McIntosh, J., & Sheridan, R. (2022) · Human Gene Therapy · doi:10.1089/hum.2022.169 · Cited by 28
Gene therapy for hemophilia—opportunities and risks
Miesbach, W., Klamroth, R., Oldenburg, J., & Tiede, A. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0353 · Cited by 28
Smith-Moore, S., Neil, S. J. D., Fraefel, C., Linden, R. M., Bollen, M., Rowe, H. M., & Henckaerts, E. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721883115 · Cited by 27
Lee, Y., Conlon, T., Specht, A., Coleman, K., Brown, L. M., Estrella, A., Dambska, M., Dahlberg, K. R., & Weinstein, D. A. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-018-0199-7 · Cited by 26
Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 29
Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
Bajaj, A., & Cuchel, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17065 · Cited by 28
The Arrival of Gene Therapy for Patients with Hemophilia A
Castaman, G., Minno, G. D., CRISTOFARO, R. D., & Peyvandi, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810228 · Cited by 27
Long, B. R., Robinson, T. M., Day, J. R., Yu, H., Lau, K., Imtiaz, U., Patton, K. S., de Hart, G., Henshaw, J., Agarwal, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.033 · Cited by 29
Self-citationDirected evolution of adeno-associated virus 5 capsid enables specific liver tropism
Wang, Y., Yang, C., Hu, H., Chen, C., Yan, M., Ling, F., Wang, K. C., Wang, X., Deng, Z., Zhou, X., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.017 · Cited by 27
Barbon, E., Aymé, G., Mohamadi, A., Ottavi, J., Kawecki, C., Casari, C., Verhenne, S., Marmier, S., van Wittenberghe, L., Charles, S., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911298 · Cited by 28
Laboratory issues in gene therapy and emicizumab
Bowyer, A. E., Lowe, A. E., & Tiefenbacher, S. (2020) · Haemophilia · doi:10.1111/hae.13976 · Cited by 26
Chauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05599-5 · Cited by 25
Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors
Merlin, S., & Follenzi, A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.013 · Cited by 25
Aronson, S. J., Bakker, R. S., Moenis, S., van Dijk, R., Bortolussi, G., Collaud, F., Shi, X., Duijst, S., ten Bloemendaal, L., Ronzitti, G., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.002 · Cited by 25
Hemophilia: A Review of Perioperative Management for Cardiac Surgery
Kwak, J., Mazzeffi, M. A., Boggio, L. N., Simpson, M. L., & Tanaka, K. A. (2020) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2020.09.118 · Cited by 25
Gene Therapy for Inherited Bleeding Disorders
Arruda, V. R., Weber, J., & Samelson‐Jones, B. J. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722862 · Cited by 25
Hemophilia A (Factor VIII Deficiency)
Seaman, C. D., Xavier, F., & Ragni, M. V. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.07.006 · Cited by 25
Hemophilia Gene Therapy Value Assessment: Methodological Challenges and Recommendations
Garrison, L. P., Pezalla, E., Towse, A., Yang, H., Faust, E., Wu, E. Q., Li, N., Sawyer, E. K., & Recht, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.008 · Cited by 25
Chen, X., Niu, X., Liu, Y., Zheng, R., Yang, L., Lu, J., Yin, S., Wei, Y., Pan, J., Sayed, A. M. M., et al. (2022) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2022.06.001 · Cited by 25
Neonatal gene therapy achieves sustained disease rescue of maple syrup urine disease in mice
Pontoizeau, C., Sola, M. S., Gaborit, C., Nguyen, V., Rotaru, I., Tual, N., Colella, P., Girard, M., Biferi, M. G., Arnoux, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30880-w · Cited by 26
Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications
Luo, L., Zheng, Q., Chen, Z., Huang, M., Fu, L., Hu, J., Shi, Q., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1019275 · Cited by 25
Ellsworth, J. L., Gingras, J., Smith, L. J., Rubin, H. L., Seabrook, T. A., Patel, K., Zapata, N., Olivieri, K. C., O’Callaghan, M., Chlipala, E. A., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225582 · Cited by 25
Herzog, R. W., Kuteyeva, V., Saboungi, R., Terhorst, C., & Biswas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00274 · Cited by 24
Deshpande, S., Joseph, K., Tong, J., Chen, Y., Pishko, A. M., & Cuker, A. C. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014111 · Cited by 24
Chowdary, P., Duran-Jimenez, B., Batty, P. A., Lowe, G., Jones, A., Pollard, D., Boyce, S., Motwani, J., Amirloo, B., Musgrave, K. M., et al. (2024) · Haemophilia · doi:10.1111/hae.15125 · Cited by 25
AAV9-Mediated Gene Therapy for Infantile-Onset Pompe’s Disease
Ma, X., Zhuang, L., Ma, W., Li, J., Mao, Y., Wang, J., Wang, X., Xu, J., Yu, S., Gu, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2407766 · Cited by 24
Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy
VandenDriessche, T., & Chuah, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.007 · Cited by 24
Han, S.-O., Li, S., McCall, A. L., Arnson, B., Everitt, J. I., Zhang, H., Young, S. P., ElMallah, M. K., & Koeberl, D. D. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.020 · Cited by 24
Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients
Keipert, C., Müller‐Olling, M., Gauly, F., Arras‐Reiter, C., & Hilger, A. (2020) · Clinical and Translational Science · doi:10.1111/cts.12794 · Cited by 24
Sabbata, G. D., Boisgérault, F., Guarnaccia, C., Iaconcig, A., Bortolussi, G., Collaud, F., Ronzitti, G., Sola, M. S., Vidal, P., Rouillon, J., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.005 · Cited by 25
Gene therapy for hemophilia: Current status and laboratory consequences
Batty, P. A., & Lillicrap, D. (2021) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13605 · Cited by 24
Lisjak, M., Caneva, A. D., Marais, T., Barbon, E., Biferi, M. G., Porro, F., Barzel, A., Zentilin, L., Kay, M. A., Mingozzi, F., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.785698 · Cited by 24
Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase
Cagin, U., Puzzo, F., Gómez, M. J., Moya‐Nilges, M., Sellier, P., Abad, C., van Wittenberghe, L., Danièle, N., Guerchet, N., Gjata, B., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.025 · Cited by 25
Loza, L. I. M., Cooney, A. L., Dong, Q., Randak, C. O., Rivella, S., Sinn, P. L., & McCray, P. B. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.020 · Cited by 25
Baatartsogt, N., Kashiwakura, Y., Hayakawa, M., Kamoshita, N., Hiramoto, T., Mizukami, H., & Ohmori, T. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.06.004 · Cited by 24
Wang, L., Warzecha, C. C., Kistner, A., Chichester, J. A., Bell, P. L., Buza, E. L., He, Z., Pampena, M. B., Couthouis, J., Sethi, S., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.007 · Cited by 24
Haemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 24
Hemophilia gene therapy knowledge and perceptions: Results of an international survey
Peyvandi, F., Lillicrap, D., Mahlangu, J. N., McLintock, C., Pasi, J., Pipe, S. W., Scales, W., Srivastava, A., & VandenDriessche, T. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12326 · Cited by 23
Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?
Pierce, G. F., Kaczmarek, R., Noone, D., O’Mahony, B., Page, D., & Skinner, M. W. (2020) · Haemophilia · doi:10.1111/hae.14131 · Cited by 23
Self-citationVrouwe, J. P. M., Meulenberg, J. J. M., Klarenbeek, N. B., Navas-Cañete, A., Reijnierse, M., Ruiterkamp, G., Bevaart, L., Lamers, R. J., Kloppenburg, M., Nelissen, R. G. H. H., et al. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.09.013 · Cited by 25
Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A
ten Ham, R. M. T., Walker, S. M., Soares, M. O., Frederix, G., Leebeek, F. W. G., Fischer, K., Coppens, M., & Palmer, S. J. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000679 · Cited by 23
Herzeg, A., Almeida-Porada, G. D., Charo, R. A., David, A. L., Gonzalez‐Velez, J. M., Gupta, N. M., Lapteva, L., Lianoglou, B. R., Peranteau, W. H., Porada, C. D., et al. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2127 · Cited by 24
Gene modification therapies for hereditary diseases in the fetus
Mattar, C. N. Z., Chan, J. K. Y., & Choolani, M. A. (2023) · Prenatal Diagnosis · doi:10.1002/pd.6347 · Cited by 23
Cellular stress and coagulation factor production: when more is not necessarily better
Chen, Z., Herzog, R. W., & Kaufman, R. J. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.10.005 · Cited by 24
Let-7 suppresses liver fibrosis by inhibiting hepatocyte apoptosis and TGF-β production
Song, J., Lv, H., Liu, B., Hao, M., Taylor, H. S., Zhang, X., Li, D., & Huang, Y. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101828 · Cited by 23
Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases
Berns, K. I., & Srivastava, A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.005 · Cited by 23
Hemophilia gene therapy: ushering in a new treatment paradigm?
George, L. A. (2021) · Hematology · doi:10.1182/hematology.2021000254 · Cited by 24
Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
Ito, M., Takino, N., Nomura, T., Kan, A., & Muramatsu, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88614-9 · Cited by 22
Let-7 underlies metformin-induced inhibition of hepatic glucose production
Xie, D., Chen, F., Zhang, Y., Shi, B., Song, J., Chaudhari, K., Yang, S., Zhang, G. J., Sun, X., Taylor, H. S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122217119 · Cited by 24
When Is The Price Of A Drug Unjust? The Average Lifetime Earnings Standard
Emanuel, E. (2019) · Health Affairs · doi:10.1377/hlthaff.2018.05052 · Cited by 23
Rose, M. D., Gao, K., Cortez-Toledo, E., Agu, E., Hyllen, A. A., Conroy, K. L., Pan, G., Nolta, J. A., Wang, A., & Zhou, P. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0261 · Cited by 22
Current and emerging gene therapies for haemophilia A and B
Kaczmarek, R., Miesbach, W., Ozelo, M. C., & Chowdary, P. (2024) · Haemophilia · doi:10.1111/hae.14984 · Cited by 21
Gene therapy for age-related macular degeneration: a promising frontier in vision preservation
Hushmandi, K., Lam, H. Y., Wong, W., Tan, W., Daryabari, S., Reiter, R. J., Farahani, N., & Kumar, A. P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02246-4 · Cited by 25
Self-citationMiracle of haemophilia drugs: Personal views about a few main players
Mannucci, P. M. (2018) · Haemophilia · doi:10.1111/hae.13519 · Cited by 21
Cadé, M., Muñoz-García, J., Babuty, A., Fouassier, M., Heymann, M., Monahan, P. E., & Heymann, D. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.015 · Cited by 21
Quinn, J., Delaney, K. A., Wong, W. Y., Miesbach, W., & Bullinger, M. (2022) · Patient Related Outcome Measures · doi:10.2147/prom.s357555 · Cited by 21
Self-citationBenefits and limitations of extended plasma half-life factor VIII products in hemophilia A
Mannucci, P. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1723547 · Cited by 21
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY
Doshi, B. S., Arruda, V. R., & Arruda, V. R. (2020) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2020.069 · Cited by 22
Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes
Lewis, C. J., Dixit, B., Batiuk, E., Hall, C. J., O'Connor, M. S., & Boominathan, A. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101429 · Cited by 20
O’Hara, J., Noone, D., Jain, M. M., Pedra, G., Landis, S., Hawes, C. R., Burke, T., & Camp, C. (2021) · Haemophilia · doi:10.1111/hae.14302 · Cited by 21
Santagostino, E., Young, G. A., Carcao, M. D., Mannucci, P. M., Halimeh, S., & Austin, S. K. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2018.1419862 · Cited by 20
Current and emerging biologics for the treatment of hereditary angioedema
Perego, F., Wu, M. A., Valerieva, A., Caccia, S., Suffritti, C., Zanichelli, A., Bergamaschini, L. C., & Cicardi, M. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1595581 · Cited by 20
Smith, B. M., Lyle, M. J., Chen, A. C., & Miao, C. H. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14659 · Cited by 20
Characterization and visualization of murine coagulation factor VIII-producing cells in vivo
Hayakawa, M., Sakata, A., Hayakawa, H., Matsumoto, H., Hiramoto, T., Kashiwakura, Y., Baatartsogt, N., Fukushima, N., Sakata, Y., Suzuki‐Inoue, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94307-0 · Cited by 20
Ozelo, M. C., Mason, J. A., Dunn, A. L., Villaça, P. R., Shen, M., Agarwal, S., Imtiaz, U., Liu, H., & Robinson, T. M. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.12.038 · Cited by 19
Viral vector‐based gene therapies in the clinic: An update
Park, K. S., Cho, Y., Mitragotri, S., & Zhao, Z. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70106 · Cited by 19
Minimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
Cao, W., Dong, B., Horling, F., Firrman, J., Lengler, J., Klugmann, M., de la Rosa, M., Wu, W., Qizhao, W., Wei, H., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.013 · Cited by 21
CRISPR/Cas9-Mediated in vivo Genetic Correction in a Mouse Model of Hemophilia A
Luo, S., Li, Z., Dai, X., Zhang, R., Liang, Z., Li, W., Zeng, M., Su, J., Wang, J., Liang, X., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.672564 · Cited by 19
The intersection of vector biology, gene therapy, and hemophilia
Lisowski, L., Staber, J. M. R., Wright, J. F., & Valentino, L. A. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12586 · Cited by 19
Schwab, M. E., & MacKenzie, T. C. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000655 · Cited by 20
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
Sternberg, A. R., Martos-Rus, C., Davidson, R. J., Liu, X., & George, L. A. (2024) · Nature Communications · doi:10.1038/s41467-024-51296-8 · Cited by 23
CRISPR Systems Suitable for Single AAV Vector Delivery
Stevanovic, M., Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Current Gene Therapy · doi:10.2174/1566523221666211006120355 · Cited by 19
Astermark, J., Blatný, J., Königs, C., Hermans, C. R. J. R., Jiménez‐Yuste, V., & Hart, D. P. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231165857 · Cited by 18
Clinical pharmacology of emicizumab for the treatment of hemophilia A
Yoneyama, K., Schmitt, C., Portron, A., Kiialainen, A., Kotani, N., Jaminion, F., Retout, S., & Adamkewicz, J. I. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2243213 · Cited by 18
Ragni, M. V., & George, L. A. (2019) · Haemophilia · doi:10.1111/hae.13717 · Cited by 18
Pierce, G. F., Pasi, J., Coffin, D., Kaczmarek, R., Lillicrap, D., Mahlangu, J. N., Rotellini, D., Sannié, T., Srivastava, A., VandenDriessche, T., et al. (2020) · Haemophilia · doi:10.1111/hae.13971 · Cited by 18
Self-citationManagement of haemophilia A with inhibitors: A regional cross‐talk
Peyvandi, F., Kavaklı, K., El-Beshlawy, A. M., & Rangarajan, S. (2022) · Haemophilia · doi:10.1111/hae.14638 · Cited by 18
Self-citation
Metadata
- Authors
- Rangarajan, S., Walsh, L., Lester, W., Perry, D., Madan, B., Laffan, M., Yu, H., Vettermann, C., Pierce, G. F., Wong, W. Y., & Pasi, K. J.
- Affiliations
- University Hospitals Birmingham NHS Foundation Trust (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-28
- Volume
- 377
- Issue
- 26
- Pages
- 2519-2530
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2775538622
- Cited by
- 694
- References
- 29
- Citations by year
- 2026: 33 · 2025: 59 · 2024: 65 · 2023: 57 · 2022: 95 · 2021: 81 · 2020: 112 · 2019: 90 · 2018: 95 · 2017: 5
- FWCI
- 63.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- BioMarin Pharmaceutical
- University Hospitals Birmingham NHS Foundation Trust
- National Institute for Health and Care Research
- University of Cambridge
- Imperial College London
- Imperial College Healthcare NHS Trust
- Barts Health NHS Trust
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, gene therapy, factor VIII, B-domain-deleted factor VIII, codon optimization, annualized bleeding rate, factor VIII activity, dose escalation, alanine aminotransferase elevation, chronic arthropathy, neutralizing antibodies
- MeSH terms
- Dependovirus, Adult, Antibodies, Viral, DNA, Viral, Factor VIII, Genetic Vectors, Hemophilia A, Hemorrhage, Humans, Infusions, Intravenous, Male, Genetic Therapy, Virus Shedding, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
